Press releases

Orchard Therapeutics announces that OTL-101 has received a designation as Promising Innovative Medicine by UK’s regulatory agency

Orchard Therapeutics Limited (“Orchard”), today announces that the UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) granted a Promising Innovative Medicine Designation to OTL-101

Read more

Orchard Therapeutics appoints Mark Rothera as CEO

Orchard Therapeutics today announces the appointment of Mark Rothera as President and Chief Executive Officer

Read more

Orchard Therapeutics announces that OTL-101 has received a Rare Paediatric Disease Designation

The US Food and Drug Administration (FDA) granted a Rare Paediatric Disease Designation to OTL-101 for the treatment of adenosine deaminase severe combined immunodeficiency, commonly known as ADA-SCID or “bubble baby” disease

Read more

Orchard Therapeutics Ltd. Announces a Manufacturing Services Agreement with PCT Cell Therapy Services, LLC

Orchard Therapeutics Limited announces on May 30th that it has entered a new clinical manufacturing services agreement with PCT Cell Therapy Services, LLC (“PCT”), a Hitachi Group Company

Read more

Orchard Therapeutics Ltd. Announces a Manufacturing Alliance with PharmaCell B.V.

Orchard Therapeutics announces today an alliance with PharmaCell B.V. (“PharmaCell”), a leading Contract Manufacturing Organization (CMO) for Cell and Gene Therapies and Regenerative Medicine

Read more